Narusheniya v sisteme gemostaza pri sakharnom diabete i puti ikh korrektsii pri naznachenii kombinirovannoy terapii Diabetonom MV i metforminom
https://doi.org/10.14341/2072-0351-5995
Abstract
Для больных сахарным диабетом характерно атеротромботическое состояние, обусловленное множественными нарушениями в системе гемостаза. Гемостатические нарушения у больных сахарным диабетом являются обычно комплексными и включают активацию естественных механизмов системы коагуляции, подавление фибринолитической активности, а также различные нарушения функции тромбоцитов
About the Authors
Alexander Sergeevich Ametov
РМАПО Росздрава, Москва
O L Solov'eva
РМАПО Росздрава, Москва
References
1. Haffner S.M., Lehto S., Ronnemaa T. Mortality from coronary heart disease in subjects with type - 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl. J Med. 1998; 339: 229-234.
2. Malmberg K.,Yusuf S.,Gerstein H.C. Impact of diabetes on Long - term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: resuits of the OASIS. Circulation.2000 Aug 29;102(9):1014-9.
3. el Khawand C., Jamart J., Donckier J. et al. Hemostasis variables in type I diabetic patients without demonstrable vascular complications. // Diabetes Care, Vol 16, Issue 8 1137-1145.
4. Folsom A., Wu K., Rassmusen M. Determinants of population changes in fibrinogen and factor VII over 6 year. Thrombosis. 2000;20:601.
5. Assmann G., Cullen P., Heinrich J. Hemostatic variables in the prediction of coronary risk: results of PROCAM. Isr J Med Sci.1996; 32(6): 364-70.
6. Ceriello A., Giugliano D., Quatraro. Blood glucose may condition VII level in diabetic and normal subjects. Diabetologia. 1988;31(12):889-91.
7. Erem C., Hacihasanoglu A., Celik S. et al. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications // Med Princ Pract 2005 Jan-Feb; 14(1): 22-30.
8. Kannel W.B., D Agostino R.B., Wilson P.W. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J.1990;120:672-676.
9. Ganda O.P., Arkin C.H. Hyperfibrinogenaemia an important risk factor for vascular complications in diabetes. Diabetes Care.1992;15:1245-1250.
10. Acang N., Jalil F.D. Hypercoagulation in diabetes mellitus. // Southeast Asian J Trop Med Public Health 1993; 24 Suppl 1: 263-266.
11. Nakag - Icindic E, Valjevac A, Lepara O. Metabolic syndrom and plazma fibrinogen in type 2 diabetic patients. Med Arh. 2007;61(1): 7-10.
12. Kozek E., Katra B., Malecri M. Rev Diabet Stud. 2004;1(3):122-8.
13. Corrado E., Rizzo M., Muratori I. Assosiation of elevated fibrinogen and CRP levels with carotid lesions in patients with newly diagnosed hypertension or type 2 diabetes. Arch Med Res. 2006;3798):1004-9.
14. Mc Gill J., Schneider D., Arfken C. Factors responsible for impared fibrinolysis in obese subjects and NIDDM patients. // Diabetes, Vol 43, Issue 1 104-10.
15. Potter van Loon B., Kluft C., Radder J., Blankenstein M., Meinders A. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin-resistance. // Metabolism 1993 Aug; 42(8):945-949.
16. Gray R., Panahloo A., Mohamed-Ali V. Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction. // Atherosclerosis 1997 Apr; 130(1-2): 171-178.
17. Juhan - Vague I.,Thompson S. G., Jespersen J. Involvment of hemostatic in the insulin resistance syndrom. Arterioscler Thromb.1993;13:1865-1873.
18. Landin K., Stigendal L., Eriksson E. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated PAI -1. Metabolism. 1990;39:1044-1048.
19. Grant P.J. J Intern Med. 2007;262(2):157-72.
20. Pandolfi A., Giaccari A., Cilli C. Acute hyperglycemia decrease plasma fibrinolytic activity and increase PAI -1 . Acta Diabetol. 2001;38:71-6.
21. Heldgaard P.E., Sidelmann J.J., Hindsberger N. Relationalship of glucose concentrations with PAI-1 and t-PA in subjects with normal glucose tolerance. Diabet Med. 2006;23(8):887-93.
22. Festa A., D. Agostino R.B., Mykkanen L. Relative contribution of insulin and its precursos to fibrinogen and PAI-1 in a large population with different states of glucose tolerance the insulin resistance atherosclerosis study (IRAS).// Arteriosclerosis, thrombosis, and vascular biology 1999; 19 : 562-568.
23. Aso Y., Wakabayashi S, Matsutomo R. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes. Diabetes Care. 2005;28(9):2211-6.
24. Trifiletti A., Lasco A., Scanardi R. Hemostasis and fibrinolysis factors in first - degree relatives of patients type 2 diabetes. Pathophysiol haemost Thromb.2002;32(3):127-30.
25. Small M., Lowe G., MacCuish A., Forbes C. Thrombin and plasmin activity in diabetes mellitus and their association with glycaemic control. // Q J Med 1987 Dec; 65(248) : 1025-1031.
26. Umpaichitra V., Hussain M.M., Castells S. PAI-1 and t-PA in minority adolesgents with type 2 diabetes and obesity. Pediatr Res. 2006;59(5) 746-50.
27. Dentaly F., Romualdy E., Ageno W. The metabolic syndrom and risk of thrombosis. Haematologica. 2007;92(3):297-9.
28. Schernthaner G., Vukovich T., Knobl P. The effect of near - normoglycaemic control on plasma levels of coagulation factor VII and anticoagulant protein C and S in diabetes patients. Br J Haematol. 1989;73(3):356-9.
29. Ceriello A., Quatraro A., Dello Russo P. Protein C deficiency in diabetes patients. Thromb Haemost. 1990;64(1):104-7.
30. Aslan B., Eren N., Cigerly S. Evaluation of protein C antigen, protein C activity and trombomodulin levels in type 2 diabetic patients. Turk J Med Sci.2005;35:305-310.
31. Ho C.H., Jap T.S. Do smoking and diabetes change the hemostatic parameters? - a study in the Chinese people. // Thromb Res 1994 Dec 15; 76(6) : 569-576.
32. Gabazza E., Takeya H., Deguchi H. et al. Protein C activation in NIDDM patients. // Diabetologia 1996 Dec; 39(12): 1455-1461.
33. Vigano S., Mannucci P.M., Dangelo A. Protein C antigen is not a acute phase reactant and is often high in ischemic heart disease and diabetes. Thromb Haemost. 1984;52(3):263-6.
34. Saito M., Kumabashiri I., Jokaji H. The levels of protein C and protein S in plasma in patients with type 2 diabetes mellitus. Thromb Res. 1988;52:479-486.
35. Knobl P., Schernthaner G., Schnak C. Haemostatic adnormalities persist despite glycaemic improvement by insulin therapy in type 2 diabetic patients. Thromb Haemost. 1994;71(6):692-7.
36. Сeriello A., Dello Russo P., Zuccotti C. Decreased antithrombin III activity in diabetes may be due to non - enzymatic glycozsylation. Thromb Haemost. 1983;50(3):633-4.
37. Gandolfo G.M., De Angelis, Torresi M.V. Determination of antithrombin III activities by differen methods in diabetic patients. Haemostasis.1980;9(1):15-9.
38. Сeriello A., Giugliano D., Dello Russo P. Metabolyc control may alter antithrombin III activity but not its plasma concentration in diabetes. Diabetes Care. 1986;9(1):32-5.
39. Carr M.E. Diabetes mellitus a hypercoagulable state. J Diabetes Complications.2001;15:44-54.
40. Сampbell O., Lavielle R., Nathan C. The mode of action and clinical pharmacology of gliclazide. Diabetes Res Clin Pract. 1991;2:21-36.
41. Rubinjoni Z., Turk Z., Coce F. Effect of platelet adhesiveness in diabetics after treatment with a new oral hypoglycaemic agent. Current Med Res Opin. 1978;5(8):625-31.
42. Hernandes Zurro, Lavielle R. Is sulphonylurea therapy effective long term? Current Med Res Opin. 1986;10(5):351-8.
43. Arfors K.E., Bergqvist D., Tangen O. Effects of gliclazide on blood platelet function. Ups J Med Sci. 1980;85:74-83.
44. Violi F., De Mattia G., Alessandri C. The effects of gliclazide on blood platelet function in patients with diabetes mellitus. Current Med Res Opin. 1982;8(3):200-3.
45. Chan T.K., Chan V., Teng C.S. The effects of gliclazide and glibenclamide on platelet function,fibrinolysis in patients with diabetes mellitus. Sem Hop. 1982;58(19):1197-200.
46. Almer L.O. The effects of chlorpropamide gliclazide and glibenclamide on t-PA in patients with diabetes. Thromb Res. 1984;35(1):19-25.
47. Gram J., Jaspersen J. Increased fibrinolytic potentional inductd gliclazide in type 1 and 2 diabetic patients. Am J Med. 1991;90:62-66.
48. Ziegler O., Drouin P. Hemobiological activity of gliclazide in diabetes mellitus. Diabetes Res Clin Pract. 1991;14:83-9.
49. Colwell J. Treatment for the procoagulant state in type 2 diabetes. // Endocrinol Metab Clin North Am 2001 Dec; 30(4): 1011-1030.
50. Vague P., Juhan - Vague I., Alessi M.C. Metformin decreases the high PAI-1 capacity, plasma insulin in nin-diabetic obese subjects. Thromb Haemost.1987;57(3):326-8.
51. Standeven K., Ariens R., Whitaker P. et al. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. // Diabetes 2002 Jan; 51(1): 189-197.
52. Gregorio F., Ambrosi S., Velussi M. Poorly controlled eldery type 2 diabetic patientsa: the effects of increasing sulphonylurea dosages or adding metformin. Diabet Met. 199;16(12):1016-24.
Review
For citations:
Ametov A.S., Solov'eva O.L. Narusheniya v sisteme gemostaza pri sakharnom diabete i puti ikh korrektsii pri naznachenii kombinirovannoy terapii Diabetonom MV i metforminom. Diabetes mellitus. 2007;10(3):33-39. (In Russ.) https://doi.org/10.14341/2072-0351-5995
Views:
19576
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
